Trials / Completed
CompletedNCT02320149
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 968 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 9 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarecycline | 1.5 mg/kg/day taken orally at the same time each day, |
| DRUG | Placebo | Placebo-matching sarecycline tablets taken orally at the same time each day. |
Timeline
- Start date
- 2014-12-18
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2014-12-19
- Last updated
- 2019-02-15
- Results posted
- 2018-05-17
Locations
57 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02320149. Inclusion in this directory is not an endorsement.